These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies. Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785 [TBL] [Abstract][Full Text] [Related]
3. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience. Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652 [TBL] [Abstract][Full Text] [Related]
4. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here? Stevens JL Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225 [TBL] [Abstract][Full Text] [Related]
5. Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredTox group. Mulrane L; Rexhepaj E; Smart V; Callanan JJ; Orhan D; Eldem T; Mally A; Schroeder S; Meyer K; Wendt M; O'Shea D; Gallagher WM Exp Toxicol Pathol; 2008 Aug; 60(4-5):235-45. PubMed ID: 18479893 [TBL] [Abstract][Full Text] [Related]
6. In silico methods for early toxicity assessment. Merlot C Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270 [TBL] [Abstract][Full Text] [Related]
7. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing. Kroeger M Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220 [TBL] [Abstract][Full Text] [Related]
8. Fluorescence-integrated transmission electron microscopy images: integrating fluorescence microscopy with transmission electron microscopy. Sims PA; Hardin JD Methods Mol Biol; 2007; 369():291-308. PubMed ID: 17656756 [TBL] [Abstract][Full Text] [Related]
9. Tuning of the Zernike phase-plate for visualization of detailed ultrastructure in complex biological specimens. Fukuda Y; Fukazawa Y; Danev R; Shigemoto R; Nagayama K J Struct Biol; 2009 Dec; 168(3):476-84. PubMed ID: 19732832 [TBL] [Abstract][Full Text] [Related]
10. Ultrastructural imaging of cell fusion in Caenorhabditis elegans. Ems S; Mohler WA Methods Mol Biol; 2008; 475():245-62. PubMed ID: 18979248 [TBL] [Abstract][Full Text] [Related]
11. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals. Claude JR; Claude N Toxicol Lett; 2004 Jun; 151(1):25-8. PubMed ID: 15177637 [TBL] [Abstract][Full Text] [Related]
12. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Sasseville VG; Lane JH; Kadambi VJ; Bouchard P; Lee FW; Balani SK; Miwa GT; Smith PF; Alden CL Chem Biol Interact; 2004 Nov; 150(1):9-25. PubMed ID: 15522258 [TBL] [Abstract][Full Text] [Related]
13. New and unconventional approaches for advancing resolution in biological transmission electron microscopy by improving macromolecular specimen preparation and preservation. Massover WH Micron; 2011 Feb; 42(2):141-51. PubMed ID: 20598558 [TBL] [Abstract][Full Text] [Related]
14. Metabolic profiling as a tool for understanding mechanisms of toxicity. Clarke CJ; Haselden JN Toxicol Pathol; 2008 Jan; 36(1):140-7. PubMed ID: 18337232 [TBL] [Abstract][Full Text] [Related]
15. The role of the toxicologic pathologist in the biopharmaceutical industry. van Tongeren S; Fagerland JA; Conner MW; Diegel K; Donnelly K; Grubor B; Lopez-Martinez A; Bolliger AP; Sharma A; Tannehill-Gregg S; Turner PV; Wancket LM Int J Toxicol; 2011 Oct; 30(5):568-82. PubMed ID: 21878555 [TBL] [Abstract][Full Text] [Related]
16. Application of genomics in preclinical drug safety evaluation. Lord PG; Nie A; McMillian M Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814 [TBL] [Abstract][Full Text] [Related]
17. Role of the study pathologist. Weber K Toxicol Pathol; 2014 Jan; 42(1):276-7. PubMed ID: 24334675 [TBL] [Abstract][Full Text] [Related]
18. Safety assessment of drug residues. Jackson BA J Am Vet Med Assoc; 1980 May; 176(10 Spec No):1141-4. PubMed ID: 6894293 [TBL] [Abstract][Full Text] [Related]
19. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Kramer JA; Sagartz JE; Morris DL Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090 [TBL] [Abstract][Full Text] [Related]
20. The value of the reprocessing method of paraffin-embedded biopsies for transmission electron microscopy. Lighezan R; Baderca F; Alexa A; Iacovliev M; Bonţe D; Murărescu ED; Nebunu A Rom J Morphol Embryol; 2009; 50(4):613-7. PubMed ID: 19942955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]